Pebrilzo (pertuzumab)
Biosimilar
- Region
- 🇪🇺 EU
- Active substance
- pertuzumab
- Company
- Biosimilar Collaborations Ireland Limited
- Status
- Opinion
- Therapeutic area
- Breast Neoplasms
- Designations
- Biosimilar
- Application
- EMEA/H/C/006844
- ATC
- L01FD02
- Official record
- www.ema.europa.eu
Indication
Treatment of breast cancer in adults
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Phesgo Authorised · Roche Registration GmbH
- 🇪🇺 Poherdy Authorised · Organon N.V.
- 🇪🇺 Perjeta Authorised · Roche Registration GmbH
- 🇺🇸 Poherdy Approved · Shanghai Henlius Biotech
Follow Pebrilzo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.